Regulatory considerations for transporter interactions
These studies are recommended by both FDA and EMA drug-drug interaction (DDI) guidelines to evaluate transporter interactions before going into first-in-human trials. Transporter studies highlight potential issues with achieving efficacious plasma concentrations of concomitantly administered medications due to a drug's impact on absorption or distribution.
Several transporters interact with drugs in clinical use. Those recommended for testing include:
- ATP binding cassette (ABC) efflux transporters P-glycprotein (P-gp), Breast Cancer Resistance Protein (BCRP), and Bile Salt Export Pump (BSEP).
- Solute carrier (SLC) uptake transporters Organic Anion Transporter (OAT) 1 and OAT3, Organic Cation Transporter (OCT) 2, Organic Anion Transporting Polypeptide (OATP) 1B1, OATP1B3, and Multidrug and Toxin Extrusion (MATE) 1 and MATE2 K.